249 related articles for article (PubMed ID: 31586312)
21. Papillary thyroid carcinoma of thyroglossal duct cyst: a retrospective analysis.
Olímpia Cid M; Carvalho Martins A; Zagalo C; Leite V; Brito JA; Vera-Cruz P
Rev Laryngol Otol Rhinol (Bord); 2012; 133(4-5):213-6. PubMed ID: 24006829
[TBL] [Abstract][Full Text] [Related]
22. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
23. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
24. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
[TBL] [Abstract][Full Text] [Related]
25. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
26. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
27. Synchronous malignancies of thyroglossal duct cyst and thyroid gland.
Naik C; Basu S
Natl Med J India; 2017; 30(2):76-77. PubMed ID: 28816214
[TBL] [Abstract][Full Text] [Related]
28. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas.
Lee JI; Jang HW; Kim SW; Kim JW; Oh YL; Chung JH
Head Neck; 2013 Apr; 35(4):548-53. PubMed ID: 22488961
[TBL] [Abstract][Full Text] [Related]
29. Ectopic papillary thyroid carcinoma within a thyroglossal duct cyst: A case report.
Roehlen N; Takacs S; Ebeling O; Seufert J; Laubner K
Medicine (Baltimore); 2017 Dec; 96(48):e8921. PubMed ID: 29310383
[TBL] [Abstract][Full Text] [Related]
30. Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas.
Kwak JY; Jeong JJ; Kang SW; Park S; Choi JR; Park SJ; Kim EK; Chung WY
Head Neck; 2013 Nov; 35(11):1630-3. PubMed ID: 23161556
[TBL] [Abstract][Full Text] [Related]
31. [Papillary carcinoma developed in the wall of a thyroglossal duct cyst].
Daou R; Aftimos G; Rahayel L
Ann Chir; 1996; 50(2):162-4. PubMed ID: 8762267
[TBL] [Abstract][Full Text] [Related]
32. Follicular variant of papillary thyroid carcinoma with B-type Raf(V600E) showing higher frequency of suspicious sonographic features and multifocality.
Shin DY; Kim KJ; Chang S; Kim H; Hwang S; Kim W; Bae J; Park S; Kang SW; Chung WY; Lee EJ
Head Neck; 2015 Nov; 37(11):1590-5. PubMed ID: 24909403
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
[TBL] [Abstract][Full Text] [Related]
34. [Papillary carcinoma in thyroglossal duct cyst remnant: review of the literature and presentation of a clinical case].
Scandroglio I; d'Atri C; Armiraglio L; Massazza C; Colombo L; Branchini L; Lampertico P; Fattovich G
G Chir; 1990; 11(7-8):425-8. PubMed ID: 2282277
[TBL] [Abstract][Full Text] [Related]
35. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.
Russo M; Malandrino P; Nicolosi ML; Manusia M; Marturano I; Trovato MA; Pellegriti G; Frasca F; Vigneri R
Thyroid; 2014 Aug; 24(8):1267-74. PubMed ID: 24787545
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the expression levels of BRAF
Tran TV; Dang KX; Pham QH; Nguyen UD; Trinh NTT; Hoang LV; Ho SA; Nguyen BV; Nguyen DT; Trinh DT; Tran DN; Orpana A; Stenman UH; Stenman J; Ho TH
BMC Cancer; 2020 May; 20(1):368. PubMed ID: 32357861
[TBL] [Abstract][Full Text] [Related]
38. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
39. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology.
Johnson SJ; Hardy SA; Roberts C; Bourn D; Mallick U; Perros P
Cytopathology; 2014 Jun; 25(3):146-54. PubMed ID: 24417615
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.
Koperek O; Kornauth C; Capper D; Berghoff AS; Asari R; Niederle B; von Deimling A; Birner P; Preusser M
Am J Surg Pathol; 2012 Jun; 36(6):844-50. PubMed ID: 22592144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
